Cancer Medicine

Cancer Medicine is an open-access interdisciplinary oncology journal published by Wiley since 2012 and covering clinical cancer research, cancer biology, cancer prevention and bioinformatics, with a 2025 journal impact factor of 3.5（Cancer Medicine，简称 Cancer Med.）是 Wiley 于 2012 年创办的开放获取跨学科肿瘤学期刊，覆盖临床肿瘤研究、肿瘤生物学、癌症预防与生物信息学，2025 年影响因子为 3.5。

Scope

• Clinical cancer research, including translational research, clinical trials, chemotherapy, radiation therapy and surgical therapy临床肿瘤研究，包括转化研究、临床试验、化疗、放疗与外科治疗。
• Clinical observations, clinical guidelines, genetic consultation and ethical considerations临床观察、临床指南、遗传咨询与伦理考量。
• Cancer biology, including molecular biology, cellular biology, molecular genetics, genomics, immunology and epigenetics肿瘤生物学，包括分子生物学、细胞生物学、分子遗传学、基因组学、免疫学与表观遗传学。
• Metabolic studies, proteomics, cytopathology, carcinogenesis and drug discovery and delivery代谢研究、蛋白质组学、细胞病理学、癌发生以及药物发现与递送。
• Cancer prevention, including behavioural science, psychosocial studies, screening, nutrition, epidemiology and prevention and community outreach癌症预防，包括行为科学、心理社会研究、筛查、营养、流行病学与预防以及社区服务。
• Bioinformatics, including gene expression profiles, gene regulation networks, genome bioinformatics, pathway analysis and prognostic biomarkers生物信息学，包括基因表达谱、基因调控网络、基因组信息学、通路分析与预后生物标志物。

History

• Launched by Wiley-Blackwell in 2012 with the support of the American Cancer Society, the Union for International Cancer Control and the Japanese Cancer Association2012 年由 Wiley-Blackwell 推出，获得美国癌症学会、国际抗癌联盟与日本癌症协会的支持。
• It was introduced as a Wiley Open Access title and has been fully open access since its foundation该刊以 Wiley Open Access 形式推出，自创刊起即为纯开放获取。
• The founding editor-in-chief was Qingyi Wei, then at the University of Texas MD Anderson Cancer Center and later at the Duke Cancer Institute首任主编为 Qingyi Wei，创刊时任职于德克萨斯大学 MD 安德森癌症中心，后长期任职于杜克癌症研究所。^[1]
• The journal is issued monthly, with one volume per year该刊每月一期，每年一卷。
• It participates in a manuscript transfer programme through which suitable papers rejected elsewhere may be transferred with editor recommendation and referee reports该刊参与稿件转投机制，优质被拒稿可在编辑推荐下携评审意见转投。

Editors

• The editor-in-chief is Stephen Tait, Professor of Mitochondrial Cancer Biology at the Institute of Cancer Sciences of the University of Glasgow, working on how mitochondria regulate cancer cell death and inflammation现任主编 Stephen Tait，格拉斯哥大学癌症科学研究所教授，研究方向为线粒体如何调控癌细胞死亡与炎症。
• The co-editor-in-chief is Sumit Sharma of John Wiley & Sons in Copenhagen共同主编为 Sumit Sharma，任职于 Wiley 哥本哈根办公室。
• The editorial board has about forty members organised into three sections, namely clinical cancer research, cancer biology and cancer prevention, with a separate 16-member editorial advisory board编委会约四十人，按临床肿瘤研究、肿瘤生物学与癌症预防三个板块编排，另有十六人的编辑顾问委员会。
• Board members and advisers come from countries including the United States, China, the United Kingdom, Italy, South Korea and Australia, forming an international editorial team编委与顾问来自美国、中国、英国、意大利、韩国与澳大利亚等国，构成国际化的编辑团队。
• Review is single-anonymized and no pre-submission enquiry is required, except that papers presenting a single microRNA or long non-coding RNA as a cancer biomarker must first submit a preliminary enquiry on their mechanistic value采用单盲评审，不强制投稿前咨询；仅当论文以单个微小 RNA 或长链非编码 RNA 作为癌症标志物时，须先提交初步咨询以说明其机制价值。